135 related articles for article (PubMed ID: 31655209)
1. Overcoming challenges in co-formulation of proteins with contradicting stability profiles - EPO plus G-CSF.
Krieg D; Svilenov H; Gitter JH; Winter G
Eur J Pharm Sci; 2020 Jan; 141():105073. PubMed ID: 31655209
[TBL] [Abstract][Full Text] [Related]
2. Sustained in vivo activity of recombinant bovine granulocyte colony stimulating factor (rbG-CSF) using HEPES buffer.
Kasraian K; Kuzniar A; Earley D; Kamicker BJ; Wilson G; Manion T; Hong J; Reiber C; Canning P
Pharm Dev Technol; 2001 Aug; 6(3):441-7. PubMed ID: 11485185
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the combined effects of pegylation and glycosylation on the stability of erythropoietin using a stability-indicating SE-HPLC.
Abed HS; Al-Ghobashy MA; Fathalla FA; Salem MY
Biologicals; 2017 Nov; 50():129-136. PubMed ID: 28958787
[TBL] [Abstract][Full Text] [Related]
4. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
Garidel P; Pevestorf B; Bahrenburg S
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
[TBL] [Abstract][Full Text] [Related]
5. Freeze drying of L-arginine/sucrose-based protein formulations, part I: influence of formulation and arginine counter ion on the critical formulation temperature, product performance and protein stability.
Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
J Pharm Sci; 2015 Jul; 104(7):2345-58. PubMed ID: 25994980
[TBL] [Abstract][Full Text] [Related]
6. T
Robinson MJ; Matejtschuk P; Bristow AF; Dalby PA
Mol Pharm; 2018 Jan; 15(1):256-267. PubMed ID: 29141152
[TBL] [Abstract][Full Text] [Related]
7. Freeze-Drying of L-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an L-Arginine Chloride-Based Protein Formulation System.
Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
J Pharm Sci; 2015 Dec; 104(12):4241-4256. PubMed ID: 26422647
[TBL] [Abstract][Full Text] [Related]
8. Freeze drying formulation using microscale and design of experiment approaches: a case study using granulocyte colony-stimulating factor.
Grant Y; Matejtschuk P; Bird C; Wadhwa M; Dalby PA
Biotechnol Lett; 2012 Apr; 34(4):641-8. PubMed ID: 22187075
[TBL] [Abstract][Full Text] [Related]
9. Improved drug-like properties of therapeutic proteins by directed evolution.
Buchanan A; Ferraro F; Rust S; Sridharan S; Franks R; Dean G; McCourt M; Jermutus L; Minter R
Protein Eng Des Sel; 2012 Oct; 25(10):631-8. PubMed ID: 22942395
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the effects of buffer conditions and extremolytes on thermostability of granulocyte colony-stimulating factor using high-throughput screening combined with design of experiments.
Ablinger E; Hellweger M; Leitgeb S; Zimmer A
Int J Pharm; 2012 Oct; 436(1-2):744-52. PubMed ID: 22850292
[TBL] [Abstract][Full Text] [Related]
11. Selective Stabilization and Destabilization of Protein Domains in Tissue-Type Plasminogen Activator Using Formulation Excipients.
Robinson MJ; Matejtschuk P; Longstaff C; Dalby PA
Mol Pharm; 2019 Feb; 16(2):744-755. PubMed ID: 30565948
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte-colony stimulating factor maintains a thermally stable, compact, partially folded structure at pH2.
Kolvenbach CG; Narhi LO; Philo JS; Li T; Zhang M; Arakawa T
J Pept Res; 1997 Oct; 50(4):310-8. PubMed ID: 9352469
[TBL] [Abstract][Full Text] [Related]
13. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations.
Roy S; Jung R; Kerwin BA; Randolph TW; Carpenter JF
J Pharm Sci; 2005 Feb; 94(2):382-96. PubMed ID: 15614819
[TBL] [Abstract][Full Text] [Related]
14. Improved process for production of recombinant yeast-derived monomeric human G-CSF.
Bae CS; Yang DS; Lee J; Park YH
Appl Microbiol Biotechnol; 1999 Sep; 52(3):338-44. PubMed ID: 10531646
[TBL] [Abstract][Full Text] [Related]
15. An integrated process analytical technology (PAT) approach to monitoring the effect of supercooling on lyophilization product and process parameters of model monoclonal antibody formulations.
Awotwe Otoo D; Agarabi C; Khan MA
J Pharm Sci; 2014 Jul; 103(7):2042-2052. PubMed ID: 24840395
[TBL] [Abstract][Full Text] [Related]
16. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody.
Cleland JL; Lam X; Kendrick B; Yang J; Yang TH; Overcashier D; Brooks D; Hsu C; Carpenter JF
J Pharm Sci; 2001 Mar; 90(3):310-21. PubMed ID: 11170024
[TBL] [Abstract][Full Text] [Related]
17. Optimization of storage stability of lyophilized actin using combinations of disaccharides and dextran.
Allison SD; Manning MC; Randolph TW; Middleton K; Davis A; Carpenter JF
J Pharm Sci; 2000 Feb; 89(2):199-214. PubMed ID: 10688749
[TBL] [Abstract][Full Text] [Related]
18. Probing Microenvironmental Acidity in Lyophilized Protein and Vaccine Formulations Using Solid-state NMR Spectroscopy.
Li M; Koranne S; Fang R; Lu X; Williams DM; Munson EJ; Bhambhani A; Su Y
J Pharm Sci; 2021 Mar; 110(3):1292-1301. PubMed ID: 33249049
[TBL] [Abstract][Full Text] [Related]
19. In vitro stability of lyophilized and reconstituted recombinant activated factor VII formulated for storage at room temperature.
Nedergaard H; Vestergaard S; Jensen PT; Kristiansen MW; Jensen MB; Ostergaard PB; Norsell T; Bjerre J
Clin Ther; 2008 Jul; 30(7):1309-15. PubMed ID: 18691990
[TBL] [Abstract][Full Text] [Related]
20. Rational design of rabies vaccine formulation for enhanced stability.
Kayser V; Françon A; Pinton H; Saluzzo JF; Trout BL
Turk J Med Sci; 2017 Jun; 47(3):987-995. PubMed ID: 28618756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
